Cost-effectiveness analysis of radiofrequency therapy versus surgery for the treatment of women with urinary incontinence: a long-term evaluation in Iran [0.03%]
射频治疗与手术治疗女性尿失禁的成本效益分析：伊朗的长期评估
Leila Moazzemi Goudarzi,Soroush Dehghan,Lida Shams et al.
Leila Moazzemi Goudarzi et al.
Introduction: Urinary incontinence (UI) is a common condition among women that imposes substantial economic burdens. Although surgery is the standard treatment, radiofrequency (RF) therapy has emerged as a less invasive a...
Cost-effectiveness analysis of radiofrequency therapy versus surgery for the treatment of women with urinary incontinence: a long-term evaluation in Iran [0.03%]
射频治疗与手术治疗女性尿失禁的成本效益分析：伊朗的长期评估
Leila Moazzemi Goudarzi,Soroush Dehghan,Lida Shams et al.
Leila Moazzemi Goudarzi et al.
Introduction: Urinary incontinence (UI) is a common condition among women that imposes substantial economic burdens. Although surgery is the standard treatment, radiofrequency (RF) therapy has emerged as a less invasive a...
A comprehensive assessment of cholinesterase inhibitors for the treatment of Alzheimer's disease based on drug selection recommendations for Chinese Medical Institutions [0.03%]
基于医疗机构药物遴选推荐的胆碱酯酶抑制剂治疗阿尔茨海默病的综合评估
Jieqiong Lv,Xianbin Cai,Zhaopeng Yang et al.
Jieqiong Lv et al.
Background: Cholinesterase inhibitors (ChEIs) are widely used to treat Alzheimer's disease (AD), yet the optimal choice remains unclear. Research design a...
Regulatory approval trends and market access implications: a multiregional comparative framework for new and supplemental drug applications (2020-2025) [0.03%]
监管审批趋势及市场准入影响：新药和续申请的多区域比较框架（2020-2025）
Mohit Bajaj,Mital Patel
Mohit Bajaj
Background: Drug approval remains fragmented, governed by region-specific regulatory frameworks and review pathways. Despite international harmonization, the same product is often approved at different timelines and under...
Principles of selecting cost-effectiveness thresholds in price-taker countries [0.03%]
自定价国家成本效益门槛的选择原则
Zoltán Kaló,Maureen Rutten-van Mölken,Eline Aas et al.
Zoltán Kaló et al.
Introduction: Countries with relatively small market size lack the bargaining power to influence the prices set by multinational pharmaceutical companies, so they function as price-taker rather than price-maker. For price...
Review and guidance for presenting cost-utility analysis with small QALY gains [0.03%]
小QALY增量的成本效用分析报告和指导指引
Xuanqian Xie,Olga Gajic-Veljanoski,Myra Wang et al.
Xuanqian Xie et al.
Background: The quality-adjusted life-year (QALY) is a preferred measure of effectiveness in health economic evaluations. Challenges arise when QALY gains are small, such as an unstable estimate of the incremental cost-ef...
Factors associated with renewal outcomes for anti-cancer drugs in China's national reimbursement drug list negotiation: a retrospective observational study [0.03%]
中国国家医保药品目录谈判中抗癌药物续约结果的影响因素分析：回顾性观察研究
An-Ping Guo,Zhen-Zhen Pan,Han-Lu Zhang et al.
An-Ping Guo et al.
Background: Price negotiation improves access to innovative anti-cancer drugs in China but pressures healthcare funds. Renewal negotiation balances cost and access, with success defined as entering a new two-year agreemen...
Population-level trends in melanoma Burden, stage at diagnosis, and indirect costs in Croatia: a descriptive analysis [0.03%]
克罗地亚黑色素瘤负担、诊断分期和间接费用的人口水平趋势描述性分析
Goran Bencina,Marija Buljan,Boris Bencina et al.
Goran Bencina et al.
Background: Croatia has among the highest melanoma mortality rates in the European Union. This study examined temporal trends in melanoma stage at diagnosis, disease burden, and indirect costs in Croatia. ...
Economic evaluations of assisted reproductive technologies (ART) for specialized infertility treatment: a systematic review of IVF, IUI and ICSI [0.03%]
辅助生殖技术（ART）的经济学评估——系统综述：IVF、IUI和ICSI在特殊不孕症治疗中的应用
Mehdi Khakian,Aghdas Souresrafil,Farahnaz Farzaneh et al.
Mehdi Khakian et al.
Introduction: Couples suffering from infertility range between 10 and 15% worldwide. As assisted reproductive technologies revolutionize treatment, this systematic review synthesizes economic evaluations of these ART meth...
Health impact and cost-effectiveness analysis of introducing a national immunization program with 21-valent versus 20-valent pneumococcal conjugate vaccines for adults ≥65 years of age in Denmark [0.03%]
丹麦老年人群体中引入21价和20价肺炎球菌结合疫苗国家免疫规划的卫生经济效果分析
Oluwaseun Sharomi,Rachel J Oidtman,John C Lang et al.
Oluwaseun Sharomi et al.
Background: Streptococcus pneumoniae is a vaccine-preventable bacterium responsible for invasive pneumococcal disease (IPD). Adults ≥65 are most susceptible to IPD, and pneumococcal vaccines may reduce morbidity and mort...